化学療法による脱毛症のために設計された水素ゲルベースの薬物投与システム
Romila Manchanda1, Alireza Aminoroaya2, Brett Volmert1
1Department of Biomedical Engineering, Michigan State University, East Lansing, MI 48824, USA; Institute for Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, MI 48824, USA.
Biomaterials advances
|August 28, 2025
まとめ
リドカインとアドレナロンで満たされた新しいヒドロゲルは,頭皮の血管を効果的に収縮させ,化学療法による脱毛 (脱毛) を防ぐために有望で非侵襲的な治療法を提供します.
科学分野:
- 生物医学工学
- 皮膚科
- 薬理学について
背景:
- 化学療法による脱毛症 (CIA) は,抗がん治療の頻繁な副作用である.
- 頭皮の冷却キャップのような 現在の治療は高価で 不快で 結果も変わりません
- CIAを防ぐために 改善された患者フレンドリーな方法が必要です
研究 の 目的:
- 生物工学のヒドロゲルを開発し 評価する 局所的な応用のためのCIAを防ぐために
- リドカイン (LID) とアドレナロン (ADR) を含んだヒドロゲルの物理的,化学的,および薬物放出特性を評価する.
- 頭皮の血流を減少させるヒドロゲルの in vivo の有効性を調査する.
主な方法:
- 電子顕微鏡,レオロギー,光学分析を用いた水素ゲルの特徴化.
- 放出運動を決定する試験.
- 薬の吸収と皮膚血管収縮を評価するために,マウスモデルとフラミンゴの巨大ウサギでのin vivo研究.
主要な成果:
- 水素ゲルは,局所使用に適した毛穴性,レオロギー性,厚さ,および腫れを示した.
- 薬の放出は,ヒドロゲルの厚さに影響された二相パターンに従った.
- 局所投与はウサギの皮膚の血管直径を著しく減少させ (LIDでは約39%,ADRでは約21%),マウスの体内薬剤吸収は最小限であった.
結論:
- 開発されたヒドロゲルは,化学療法による脱毛を予防する効果的で臨床的に応用可能な方法として潜在性を示しています.
- 作用のメカニズムは,既存の治療法と同様の皮膚血管収縮ですが,投与が改善されています.
- 化学療法を受けている患者に より快適で効果的な治療法が見つかるかもしれません
関連する概念動画
Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Modified-Release Drug Delivery Systems: Classification
315
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
315
Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
208
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
208
Transdermal Drug Delivery Systems
233
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
233


